Susquehanna Portfolio Strategies LLC Sells 14,353 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

Susquehanna Portfolio Strategies LLC trimmed its position in Kodiak Sciences Inc. (NASDAQ:KOD) by 14.0% during the second quarter, HoldingsChannel.com reports. The fund owned 88,016 shares of the company’s stock after selling 14,353 shares during the period. Susquehanna Portfolio Strategies LLC’s holdings in Kodiak Sciences were worth $207,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Acadian Asset Management LLC raised its holdings in Kodiak Sciences by 14.1% in the second quarter. Acadian Asset Management LLC now owns 1,965,449 shares of the company’s stock worth $4,614,000 after purchasing an additional 242,559 shares during the period. Renaissance Technologies LLC raised its stake in Kodiak Sciences by 21.9% during the 2nd quarter. Renaissance Technologies LLC now owns 708,800 shares of the company’s stock worth $1,666,000 after buying an additional 127,400 shares during the period. Sei Investments Co. bought a new position in Kodiak Sciences during the first quarter worth about $595,000. RIA Advisory Group LLC acquired a new position in Kodiak Sciences in the first quarter valued at about $489,000. Finally, Panagora Asset Management Inc. bought a new stake in shares of Kodiak Sciences in the second quarter worth about $207,000. Institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating and set a $3.00 target price on shares of Kodiak Sciences in a report on Tuesday, September 24th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.00.

Kodiak Sciences Stock Down 1.8 %

NASDAQ:KOD opened at $2.66 on Monday. Kodiak Sciences Inc. has a 12-month low of $1.37 and a 12-month high of $7.77. The firm has a market capitalization of $139.74 million, a price-to-earnings ratio of -0.60 and a beta of 2.35. The stock’s 50 day moving average price is $2.65 and its two-hundred day moving average price is $3.26.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.86) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.01. Equities research analysts expect that Kodiak Sciences Inc. will post -3.52 EPS for the current year.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.